Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen - Related Studies

Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen

This study has been completed.

Study NCT00002429. Last updated on October 1, 2007. Information provided by Bristol-Myers Squibb

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Infection

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Lamivudine/Zidovudine
		Nelfinavir mesylate
		Stavudine
		Didanosine

5	Additional drug interventions recognized in this trial
		Nelfinavir

6	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antimetabolites
		Antiviral Agents
		Enzyme Inhibitors
		HIV Protease Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Protease Inhibitors
		Reverse Transcriptase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Bristol-Myers Squibb